MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. Klitgaard was previously a member of the Syneos Board from 2017 until May 2022, having resigned due to a personal matter. The Company also announced today that Todd M. Abbrecht is stepping down from its Board of Directors.
“We are excited to welcome Bill back to the Syneos Health Board,” said John Dineen, Chair of the Syneos Health Board of Directors. “Bill’s deep financial expertise combined with his knowledge of our company are a welcome addition to an already strong Board, enhancing its composition. This appointment will support continued successful oversight of our strategy as we speed our customers’ delivery of important therapies to patients.”
Mr. Dineen added, “Syneos Health has been well served by Todd’s contributions, and we thank him for his years of service to the Company.”
Mr. Klitgaard will serve as a Class II director and as a member of the Company’s Audit Committee. With these changes, the Syneos Health Board remains comprised of 10 directors, 9 of whom are independent.
William E. Klitgaard
Mr. Klitgaard currently serves on the board of directors of XIFIN, Inc., a health information technology company and Avista Public Acquisition Corp. II, a special purpose acquisition company, where he serves as the Chair of the Audit Committee.
Mr. Klitgaard was an Operating Executive at Avista Capital Partners, a private equity firm focused on healthcare from 2020 to 2021. He previously served as the President of Enlighten Health, a division of LabCorp from 2015 to 2016. He also held various roles over his 19-year career at Covance, including three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer. He received his Bachelor of Arts in Economics from the University of California at Berkeley, and his Masters of Science from the Sloan Management School at the Massachusetts Institute of Technology.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.
We bring together more than 29,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
| Investor Relations Contact: | Press/Media Contact: |
| Ronnie Speight | Gary Gatyas |
| Senior Vice President, Investor Relations | Executive Director, External Communications |
| +1 919 745 2745 | +1 908 763 3428 |
| Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com |
